02.12.2010 • News • Merck & Co. • Biotechnology • Mergers & Acquisitions (M&A)

Merck Set to Buy Biotech Firm SmartCells

U.S. pharmaceutical company Merck & Co. is set to buy SmartCells Inc, a privately held biotechnology firm in the early stages of developing a new diabetes drug, the Wall Street Journal reported.

The deal for SmartCells would exceed $500 million if various milestones for development, regulatory approval and sales were met and could be announced as early as Thursday, a person familiar with the matter told the Journal.

A SmartCells deal would expand Merck's treatment offerings for diabetes. It already has two top-selling drugs for Type 2 diabetics in its portfolio.

Merck could not be reached for comment.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Top-Feature